FT : Gas found in Zimbabwe by Australian energy group Invictus

Gas found in Zimbabwe by Australian energy group Invictus
Discovery of samples raises hopes that nation hit by power shortages could become a producer

Invictus Energy has discovered gas in Zimbabwe, raising hopes the landlocked southern African nation could become a producer decades after ExxonMobil abandoned a search for oil in the region.

The Australian-based company said four samples from a well in the north had shown the presence of gas in a country that has suffered severe power shortages and endured years of economic hardship.

Shares in Invictus surged 28 per cent to A$0.20 on Thursday — the highest daily rise in a year, although from a low base.

“The discovery represents one of the most significant developments in the onshore southern Africa oil and gas industry for decades,” said Scott Macmillan, managing director of Invictus.

Sydney-listed Invictus, which used data collected by Mobil before it merged with Exxon, will drill more wells at the Cabora Bassa project to find how much gas there is there — and production could be years away.

Viable gas for energy generation could help relieve the power shortages that have caused big disruptions for major miners operating in the country.

At present, platinum producers, including a unit of Anglo American, Chinese-backed lithium miners and gold companies have to pay to import electricity from abroad.

The tip of Africa has seen a renaissance in oil and gas exploration since Mozambique, Zimbabwe’s neighbour, discovered vast offshore gas finds more than a decade ago.

Discoveries onshore, where resources could be plugged into local industrialisation and not just exported to world markets, remain rare.

TotalEnergies and Shell are among the investors betting on deepwater oil discoveries in Namibia. South Africa is hoping to tap gas off its coast.

Zimbabwe might appear an unlikely candidate to join them given its forbidding reputation for abuse of resource wealth and political chaos that has persisted since the downfall of Robert Mugabe in a 2017 coup. 

Under Emmerson Mnangagwa, who was elevated to power by Zimbabwe’s military and was re-elected as president in a disputed vote this year, the country’s wealth in gold and diamonds remains tainted by allegations of systemic looting. Mnangagwa’s ruling Zanu-PF has been in power since independence in 1980.

“Historically, natural resource extraction in Zimbabwe has tended to only benefit a political elite, often at the expense of local communities and ordinary citizens, and failed to translate into development gains,” said Zimbabwe’s Centre for Natural Resource Governance in a report on the gas exploration project this year.

Invictus’s Macmillan said that gas by its nature was less susceptible to these risks. “Gas is a different type of resource because you need pipelines, infrastructure and long-term customers,” he said. “It’s a very different scenario from precious metals, which are fungible” and move more easily.

Zimbabwean pension funds are among the investors in Invictus and the company and the project will eventually need a production-sharing deal with the Zimbabwean state.

Mobil stopped exploring because “they thought that there was no way for them to commercialise gas, which was true in the early 1990s”, Macmillan said. Due to the power crisis, “we live in a very different environment now from a commercialisation perspective”.

“Often with gas developments, you have to wait for customers and markets. There are existing consumers [in Zimbabwe] who are paying hard cash to import electricity,” he added.

>>> Cytokinetics presents results from COURAGE-ALS at the 34th International Sy

Cytokinetics presents results from COURAGE-ALS at the 34th International Symposium on ALS/MND (33.46)
  • COURAGE-ALS was designed with two planned interim analyses of unblinded data by the Data Monitoring Committee. At the second interim analysis the Data Monitoring Committee recommended the discontinuation of the clinical trial due to futility. Subsequently, the Company concluded study conduct in March 2023 and discontinued treatment with reldesemtiv in all patients including those in the open-label extension study, COURAGE-ALS OLE. Development of reldesemtiv has been terminated.
  • At the time of the discontinuation of COURAGE-ALS, 486 patients had started treatment with reldesemtiv or placebo and 276 had completed dosing through 24 weeks. Treatment with reldesemtiv for 24 weeks had no effect on the primary efficacy endpoint measure of change from baseline up to Week 24 in the ALS Functional Rating Scale Revised (ALSFRS-R) (joint rank test p=0.11). Patients treated with reldesemtiv declined 5.3 points per month (SD=5.3) while patients treated with placebo declined 4.8 points per month (SD=4.4). No pre-defined patient subgroup favored treatment with reldesemtiv. Patients with a faster disease progression rate did not experience a greater treatment effect from reldesemtiv, contrary to analyses conducted post hoc from FORTITUDE-ALS, the Phase 2 clinical trial of reldesemtiv, which had suggested that treatment effects were more evident in patients with a faster disease progression rate. Reldesemtiv also demonstrated no effect on key secondary endpoints including change from baseline to Week 24 in in-clinic percent predicted forced vital capacity (FVC), ALS Questionnaire 40 (ALSAQ-40) and handgrip strength.

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • CXM -28.2%, AI -11.4%, CHWY -11.4% (also names new CFO), NAPA -9.4%, SPWH -8.8%, GME -8.8%, AGX -6.3%, GEF -6%, OXM -3.5%, CHPT -3.4%, VEEV -2.5%
Other news:
  • WVE -22.7% (prices $100 million public offering of ordinary shares)
  • NKLA -18.1% (announces $100 mln stock offering; also $200 mln convertible notes offering)
  • SEAT -13.4% (files for 18.5 mln share offering by selling shareholder)
  • HCI -5.9% (prices offering of 1.0 mln shares of common stock at $78.00 per share)
  • ETNB -5.8% (announces upsized pricing of $150.0 million public offering of common stock and pre-funded warrants)
  • CNM -4.2% (selling shareholders commence 15 mln share offering; CNM to repurchase of 3.13 mln of these shares and 1.87 mln partnership interests)
  • PYCR -3% (selling shareholder commences 5 mln share offering)
  • HIVE -2.6% (provides November production update)
  • MNOV -1.8% (receives a notice of decision to grant for a new patent covering MN-166 (ibudilast) for the treatment of progressive MS in Europe)
  • BECN -1.4% (prices secondary offering of 5 million shares of common stock)
Analyst comments:
  • DHR -1.7% (downgraded to Neutral from Buy at Goldman)
  • TTWO -1.7% (downgraded to Neutral from Buy at BofA Securities)
  • VOD -1.4% (downgraded to Underperform from Neutral at Exane BNP Paribas)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • SMTC +13.8%, VRNT +9.2%, BRZE +8.3%, JBLU +7.8% (guidance), DG +3%, CIEN +3%, BASE +1.9%
Other news:
  • ASLE +17.4% (receives Boeing 737NG Supplemental Type Certificate for its Enhanced Flight Vision System "AerAware")
  • VNDA +16.6% (acquires U.S. and Canadian rights to PONVORY (ponesimod) from Johnson & Johnson's (JNJ) Actelion Pharmaceuticals)
  • CERE +14.1% (ABBV to acquire CERE for $45/sh)
  • ANIX +4.1% (Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine)
  • AORT +3.8% (CFO retires names new CFO) CYTK +2.2% (presents results from COURAGE-ALS at the 34th International Symposium on ALS/MND)
  • FSR +2.1% (issues statement says negative reports about co have been overblown)
  • ASR +2% (reports Nov traffic)
  • FWRD +1.7% (provides mid-quarter update)
  • TRN +1.7% (increases dividend)
  • DNA +1.5% (signs MoU with Synplogen to accelerate the development of DNA manufacturing and gene therapy in Japan)
  • BHP +1.4% (CFO and executive leadership team update; Vandita Pant has been appointed Chief Financial Officer)
  • PAX +1.2% (to acquire Credit Suisse's real estate business in Brazil for ~$130 mln)
  • BMY +1.2% (increases dividend; announces additional $3 billion share repurchase authorization)
  • LEV +1.2% (announced the successful final certification for its medium duty battery pack the LionBattery MD a lithium-ion battery pack specifically designed for the Company's medium duty trucks and school buses)
  • CMPS +1.1% (study results of psilocybin published in JAMA Psychiatry)
Analyst comments:
  • VTGN +14.2% (upgraded to Buy from Hold at Jefferies)
  • BVS +5.3% (upgraded to Buy from Hold at Canaccord Genuity)
  • EQNR +2.7% (upgraded to Buy from Neutral at BofA Securities)
  • SPHR +2% (upgraded to Buy from Neutral at Seaport Research Partners)
  • DDOG +1.5% (upgraded to Buy from Hold at Stifel)
  • BIIB +1.1% (upgraded to Outperform from Mkt Perform at Raymond James)
  • SNDR +1.1% (upgraded to Equal Weight from Underweight at Wells Fargo)

>>> Europe : Brokers Upgrades & Downgrades - 7th of December 2023 V3(++)

>>> Up
* Adyen Raised to Buy at Jefferies; PT 1,396 euros
* Aiforia Technologies Raised to Accumulate at Inderes
* Deutsche Post AG Raised to Neutral at JPMorgan; PT 43.80 euros
* Epiroc Raised to Buy at DNB Markets; PT 230 kronor
* Qiagen Raised to Buy at Goldman (++)
* SEB Raised to Market Perform at KBW; PT 155 kronor
* Sika Raised to Neutral at JPMorgan; PT 237 Swiss francs
* Zug Estates Raised to Outperform at ZKB

>>> Down
* Air France-KLM Cut to Underweight at JPMorgan (+)
* Boliden Cut to Underweight at Morgan Stanley; PT 250 kronor
* BRANICKS Group AG Cut to Sell at Bankhaus Metzler; PT 3 euros (+)
* Continental Cut to Hold at HSBC; PT 75 euros
* Danaher Cut to Neutral at Goldman (++)
* IAG Cut to Underweight at JPMorgan (+)
* Kering Cut to Neutral at BNPP Exane; PT 440 euros (+)
* Kingspan Cut to Underweight at JPMorgan; PT 65 euros
* Lufthansa Cut to Underweight at JPMorgan (+)
* Petrofac Cut to Hold at SocGen; PT 26 pence
* Pierer Mobility Cut to Hold at Stifel; PT 63.66 euros
* Revenio Cut to Accumulate at Inderes; PT 25.50 euros
* Rockwool Cut to Underweight at JPMorgan; PT 1,720 kroner
* Salvatore Ferragamo Cut to Sell at Deutsche Bank; PT 11 euros
* SSAB Cut to Equal-Weight at Morgan Stanley; PT 80 kronor
* Swatch Cut to Hold at Deutsche Bank; PT 240 Swiss francs
* Telia Raised to Neutral at BNPP Exane; PT 25 kronor
* Vodafone Cut to Underperform at BNPP Exane; PT 68 pence
* Worldline Cut to Underperform at Jefferies; PT 12.30 euros
* WPP Cut to Neutral at Oddo BHF; PT 990 pence (++)

>>> Initiation
* Airbus ADRs Rated New Sell at Berenberg; PT $27
* CAF Rated New Buy at SocGen; PT 42 euros (+)
* Coca-Cola Femsa ADRs Rated New Neutral at Citi; PT $90
* CVS Group Rated New Buy at Panmure Gordon; PT 2,085 pence
* GSEO LN Rated New Neutral at Peel Hunt (+)
* Oxford Biomedica Reinstated Buy at Peel Hunt; PT 475 pence
* Vaisala Rated New Buy at Danske Bank Markets; PT 45 euros (++)

>>> Call
* Adyen Among Favored Payments Stocks at Jefferies, Worldline Cut
* Anglo, Antofagasta and Rio Tinto Citi’s Top Europe Mining Picks
* Morgan Stanley Selective in Diversifieds, Bullish on Copper
* European Telecoms Eye 2024 Cash-Flow Gains on Profit Resilience
* Goldman Strategists Say US Stocks Vulnerable to Any Macro Shock (+)
* JPMorgan Now More Cautious on Airlines, Upgrades Deutsche Post (+)
* Vodafone Falls on Exane Cut as Deals Risk Future Cash Flow (++)
* Qiagen Now a Buy at Goldman, Danaher Cut in Life Science Tools (++)

>>> Europe : Brokers Upgrades & Downgrades - 7th of December 2023 V2(+)

>>> Up
* Adyen Raised to Buy at Jefferies; PT 1,396 euros
* Aiforia Technologies Raised to Accumulate at Inderes
* Deutsche Post AG Raised to Neutral at JPMorgan; PT 43.80 euros
* Epiroc Raised to Buy at DNB Markets; PT 230 kronor
* SEB Raised to Market Perform at KBW; PT 155 kronor
* Sika Raised to Neutral at JPMorgan; PT 237 Swiss francs
* Zug Estates Raised to Outperform at ZKB

>>> Down
* Air France-KLM Cut to Underweight at JPMorgan (+)
* Boliden Cut to Underweight at Morgan Stanley; PT 250 kronor
* BRANICKS Group AG Cut to Sell at Bankhaus Metzler; PT 3 euros (+)
* Continental Cut to Hold at HSBC; PT 75 euros
* IAG Cut to Underweight at JPMorgan (+)
* Kering Cut to Neutral at BNPP Exane; PT 440 euros (+)
* Kingspan Cut to Underweight at JPMorgan; PT 65 euros
* Lufthansa Cut to Underweight at JPMorgan (+)
* Petrofac Cut to Hold at SocGen; PT 26 pence
* Pierer Mobility Cut to Hold at Stifel; PT 63.66 euros
* Revenio Cut to Accumulate at Inderes; PT 25.50 euros
* Rockwool Cut to Underweight at JPMorgan; PT 1,720 kroner
* Salvatore Ferragamo Cut to Sell at Deutsche Bank; PT 11 euros
* SSAB Cut to Equal-Weight at Morgan Stanley; PT 80 kronor
* Swatch Cut to Hold at Deutsche Bank; PT 240 Swiss francs
* Telia Raised to Neutral at BNPP Exane; PT 25 kronor
* Vodafone Cut to Underperform at BNPP Exane; PT 68 pence
* Worldline Cut to Underperform at Jefferies; PT 12.30 euros

>>> Initiation
* Airbus ADRs Rated New Sell at Berenberg; PT $27
* CAF Rated New Buy at SocGen; PT 42 euros (+)
* Coca-Cola Femsa ADRs Rated New Neutral at Citi; PT $90
* CVS Group Rated New Buy at Panmure Gordon; PT 2,085 pence
* GSEO LN Rated New Neutral at Peel Hunt (+)
* Oxford Biomedica Reinstated Buy at Peel Hunt; PT 475 pence

>>> Call
* Adyen Among Favored Payments Stocks at Jefferies, Worldline Cut
* Anglo, Antofagasta and Rio Tinto Citi’s Top Europe Mining Picks
* Morgan Stanley Selective in Diversifieds, Bullish on Copper
* European Telecoms Eye 2024 Cash-Flow Gains on Profit Resilience
* Goldman Strategists Say US Stocks Vulnerable to Any Macro Shock (+)
* JPMorgan Now More Cautious on Airlines, Upgrades Deutsche Post (+)

>>> Stoxx 600 Pre-Market Indications

  • BAT (BMT TH) +1.4%
  • Sanofi (SNW TH) +1.1%
  • Adyen (1N8 TH) +0.5%
    • Adyen Among Favored Payments Stocks at Jefferies, Worldline Cut
  • Rio Tinto (RIO1 TH) +0.3%
    • Morgan Stanley Selective in Diversifieds, Bullish on Copper
  • ING (INN1 TH) -1.3%
  • Rolls-Royce (RRU TH) -1.4%
  • Evotec SE (EVT TH) -1.4%
  • TotalEnergies (TOTB TH) -1.4%
    • Big Oil Shouldn’t Lead the Green Energy Transition: Javier Blas
  • Airbus (AIR TH) -1.4%
  • Encavis (ECV TH) -1.6%
  • Nel (D7G TH) -1.7%
  • Siemens Energy (ENR TH) -1.9%
  • Continental (CON TH) -3%
  • Lufthansa (LHA TH) -3.9%
    • Lufthansa Cut to Underweight at JPMorgan

>>> TradeGate Pre-Market Indications

DAX:
  • Infineon (IFX TH) -0.8%
    • Watch European Chipmakers as AMD Gives Eye-Popping Forecast
  • Airbus (AIR TH) -1.5%
  • Continental (CON TH) -2.3%
    • Continental Cut to Hold at HSBC; PT 75 euros
MDAX:
  • Hensoldt (HAG TH) +2.9%
  • ProSieben (PSM TH) -1%
  • Lufthansa (LHA TH) -3.6%
SDAX:
  • Metro (B4B TH) +1.1%
  • Heidelberger Druck (HDD TH) -1%
  • PVA TePla (TPE TH) -1.6%
  • Borussia Dortmund (BVB TH) -2.5%